1. Current Concepts in Individualized Care of ALK-Translocated Advanced NSCLC

2. Educational Objectives

3. Patient Case 1

4. Patient Case 1 (cont)

5. ALK Fusion Genes

6. ALK+ NSCLC

7. ALK-Targeted Treatments

8. First-Line Crizotinib

9. Crizotinib Adverse Events

10. Monitoring

11. Next Generation ALK Inhibitors Crizotinib-Naive Patients

12. Future Directions for Frontline Therapy

13. Patient Case 2

14. CNS Metastases

15. Recurrence

16. Ceritinib and Alectinib Efficacy in Crizotinib-Treated Patients

17. Ceritinib and Alectinib Toxicity

18. Managing Brain Metastases

19. Screening for ALK Rearrangements in Squamous NSCLC

20. Future Directions

21. Abbreviations

22. Abbreviations (cont)

23. Abbreviations (cont)